BioSpace News Archive

Cali Biosciences Co., Ltd. (hereinafter referred to as “Cali Biosciences”), a biopharmaceutical company focused on the research and development of innovative drugs, announced two major milestones for CPL-01, its long-acting ropivacaine for post-operative analgesia and opioid elimination/reduction.

Propanc Biopharma, Inc. today announced that Mr. James Nathanielsz, Propanc’s Chief Executive Officer and Co-Founder, will conduct investor meetings and present at the upcoming Sidoti & Company’s upcoming Micro-Cap Virtual Investor Conference, which will be held on Wednesday and Thursday, November 9 – 10, 2022.

The global Protein A resins market size was estimated at around USD 536.67 million in 2021 and it is projected to hit around USD 1.03 billion by 2030, growing at a CAGR of 7.51% from 2022 to 2030.

Parent Project Muscular Dystrophy (PPMD), a US nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), and Duchenne UK, a UK-based patient organization, are pleased to announce the launch of their 2022 Joint Call for Therapeutic Projects inviting research proposals for submission and review.

The global protein sequencing market was surpassed at USD 1.4 billion in 2021 and is expected to hit around USD 1.91 billion by 2030, growing at a CAGR of 3.51% from 2022 to 2030.

Nykode Therapeutics ASA (OSE: NYKD) today announced the presentation of positive preliminary safety and immunogenicity results from its Phase 1/2a study of VB10.NEO, a proprietary individualized therapeutic DNA cancer vaccine, in patients with locally advanced or metastatic solid tumors.

Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their participation at the Thirteenth American Conference on Pharmacometrics (ACoP13) occurring October 30th - November 2nd, 2022 in Aurora, CO.

Minerva Surgical, Inc., a woman’s health company focused on the treatment of Abnormal Uterine Bleeding, announced that it will release its third quarter 2022 financial results on Wednesday, November 9, 2022.

Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter 2022 after market close on Wednesday, November 9th, 2022.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third-quarter earnings conference call on Tuesday, Nov. 1, 2022 at 4:30 p.m. ET.